| CX3CL1 — C-X3-C Motif Chemokine Ligand 1 (Fractalkine) | |
|---|---|
| Symbol | CX3CL1 |
| Full Name | C-X3-C Motif Chemokine Ligand 1 (Fractalkine / Neurotactin) |
| Chromosome | 16q13 |
| NCBI Gene | 6376 |
| Ensembl | ENSG00000006210 |
| OMIM | 601880 |
| UniProt | P78423 |
| Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), [Multiple Sclerosis](/diseases/multiple-sclerosis) |
| Expression | [Neurons](/entities/neurons) ([cortex](/brain-regions/cortex), hippocampus), Endothelial cells, Dendritic cells |
CX3CL1 (C-X3-C Motif Chemokine Ligand 1), also known as fractalkine or neurotactin, encodes the sole member of the CX3C chemokine family. Located on chromosome 16q13, the gene produces a unique transmembrane chemokine that exists in both membrane-anchored and soluble forms, each with distinct signaling functions in the central nervous system[1].
CX3CL1 is constitutively expressed at high levels by neurons throughout the brain, particularly in the cerebral cortex, hippocampus, striatum, and thalamus. Its receptor, CX3CR1, is predominantly expressed on microglia, establishing the CX3CL1–CX3CR1 axis as a primary mechanism of neuron–microglia communication[2].
Dysregulation of CX3CL1 signaling has been implicated in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and other neurodegenerative conditions where aberrant microglial activation contributes to disease progression.
The CX3CL1 gene spans approximately 15.5 kb on chromosome 16q13 and contains three exons. The promoter region contains binding sites for NF-κB, AP-1, and CREB transcription factors, enabling activity-dependent and inflammation-responsive regulation of expression[3].
The CX3CL1 protein (373 amino acids) has a distinctive domain architecture:
A critical feature of CX3CL1 biology is its dual existence:
Membrane-anchored CX3CL1: Functions as an adhesion molecule, mediating direct cell-cell contact between neurons and microglia. Promotes microglial quiescence and neuroprotection through tonic CX3CR1 signaling[4].
Soluble CX3CL1 (sCX3CL1): Generated by proteolytic cleavage of the membrane form by ADAM10 (constitutive) and ADAM17/TACE (inducible). Soluble fractalkine acts as a chemoattractant, recruiting microglia and monocytes to sites of neuronal injury[5].
CX3CL1 serves as the primary "off" signal from neurons to microglia, maintaining microglial homeostasis in the healthy brain:
CX3CL1 exerts direct and indirect neuroprotective effects:
Soluble CX3CL1 functions as a potent chemoattractant:
CX3CL1 plays a complex, context-dependent role in Alzheimer's disease:
In Parkinson's disease, CX3CL1 modulates dopaminergic neuron vulnerability:
In ALS:
CX3CL1 shows a distinctive pattern of neuronal expression in the brain:
Expression data from the Allen Brain Atlas confirms widespread neuronal expression with regional variation correlating with vulnerability to neurodegeneration.
CX3CL1 expression is regulated by:
The CX3CL1–CX3CR1 axis presents opportunities for therapeutic intervention:
Harrison et al. Role for fractalkine/CX3CL1 in the biology of neurodegenerative diseases (2012). 2012. ↩︎
Paolicelli et al. Fractalkine regulation of microglial physiology and consequences on the brain and behavior (2014). 2014. ↩︎ ↩︎
Bhatt et al. Transcriptional regulation of CX3CL1 gene promoter (2018). 2018. ↩︎
Cardona et al. Control of microglial neurotoxicity by the fractalkine receptor (2006). 2006. ↩︎
Hundhausen et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (2003). 2003. ↩︎
Limatola & Bhatt, Chemokine CX3CL1 protects neuron–glia communication in the nervous system (2014). 2014. ↩︎
Lee et al. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models (2010). 2010. ↩︎
Bhaskar et al. Regulation of tau pathology by the microglial fractalkine receptor (2010). 2010. ↩︎
Morganti et al. The soluble isoform of CX3CL1 is necessary for neuroprotection in a mouse model of Parkinson's disease (2012). 2012. ↩︎
Cardona et al. Control of microglial neurotoxicity by the fractalkine receptor (2006). 2006. ↩︎